ZNF500

Across TCGA pan-cancer cohorts, ZNF500 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF500 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ZNF500 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF500 expression acts as an unfavorable survival marker.

CHOL, LUAD, and ESCA are the cancer types where ZNF500 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.089	0.746	<.001	36	view →
LUAD	OS	Median	All	0.223	0.788	.002	18	view →
ESCA	DFS	Median	II,III,IV	0.181	0.528	.004	12	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF500–CHOL (OS)

Open the CHOL breakdown →